Sensirion to start production of SHT21 sensor

Published: 29-Mar-2010
Regulatory

Swiss manufacturer says it is the smallest digital humidity sensor in the world

Sensirion, a Swiss manufacturer of CMOS-based sensor components and systems, is to begin serial production of the SHT21 next month (April).

The SHT21 consists of a newly designed sensor chip encapsulated in a DFN 3-0 package. With this encapsulation the chip is completely over-moulded, except for the humidity sensing area. This reduces the component’s size to 3x3mm with a height of 1.1mm. The company says it also provides protection against condensation and harsh environments, therefore giving outstanding long-term stability.

Typical sensor accuracy is ±2% RH over 20–80% RH and ±0.3 °C over 25–42°C.

A scan path routine enables detailed sensor quality checking, while individual detailed tracking information on the chip can be read out by a simple command. Additionally, the SHT21 is reflow solderable without any degradation of sensor performance. The sensor is provided on tape and reel to facilitate trouble-free handling.

See more

You may also like

Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

Read more
The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients

Trending Articles

  1. FDA considers black box warning for COVID-19 vaccines amid internal disputes The US FDA is reportedly weighing a black box warning for COVID-19 vaccines — a move that has alarmed public health leaders and vaccine manufacturers, who say no new safety signals support such action
  2. Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt) The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
  3. Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
  4. New pharmaceutical legislation in Europe agreed The agreement is the most significant overhaul of the regulatory framework in more than 20 years and represents a huge opportunity to reshape medicines regulation in the EU
  5. ten23 health QC lab to support commercial product testing for US customer following FDA approvals This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to manufacturing the commercial product

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Regulatory

New pharmaceutical legislation in Europe agreed

The agreement is the most significant overhaul of the regulatory framework in more than 20 years and represents a huge opportunity to reshape medicines regulation in the EU
Manufacturing

Why aseptic processing is critical for microsphere drug manufacturing

As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements
Regulatory

Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt

The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe
Regulatory

Regulating innovation: a new focus on digital mental health technologies (DMHTs)

IMed Consultancy’s Benjamin Austin provides a clear understanding of how digital mental health technologies are innovating care and describes the evolving regulatory frameworks that ensure their safety and effectiveness
Regulatory

ten23 health QC lab to support commercial product testing for US customer following FDA approvals

This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to manufacturing the commercial product
Subscribe now